Dear Editor A FREQUENTLY used cautionary adage among competent analysts is that “Statistics don’t lie, liars use statistics.” Quite often, this adage also ...

Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, ...

Escient’s preclinical data demonstrates that, by blocking activation of MRGPRX2, EP262 has the potential to effectively treat a broad range of mast-cell-mediated diseases, with an initial focus ...

The company wants to quickly double, and then triple, its data-center capacity, according to the confidential presentation.

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a ...

– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – ...

External Sector Statistics Financial Sector Statistics Government Finance Statistics National Accounts and Prices Statistics Securities Statistics Back to Top External Sector Statistics Balance of ...

--Wave Life Sciences Ltd., a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the presentation of ...